Journal September 16, 2026 6 min read

How to Reconstitute Ipamorelin

A laboratory-focused guide to reconstituting Ipamorelin, covering its identity as a growth hormone secretagogue, the receptor family it targets, and findings from animal and clinical studies. For research use only.

peptides-pro Editorial

Ipamorelin (also known as NNC 26-0161, ipamorelin acetate) is a synthetic pentapeptide belonging to the growth hormone secretagogue (GHS) class. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a molecular formula of C38H49N9O5 and a molecular weight of 711.85 g/mol. As a research compound, it is supplied as a lyophilized powder and requires reconstitution with a suitable solvent prior to laboratory use.

The work on Ipamorelin centres on the growth hormone secretagogue receptor 1a (GHS-R1a), a G-protein-coupled receptor that mediates ghrelin signalling. Ipamorelin acts as a GHS-R1a agonist, and studies have examined its effects on the GH-IGF-1 axis and other physiological systems in various models.

Research Studies

Ipamorelin and gastrointestinal recovery after bowel resection

A clinical trial investigated whether post-operative administration of Ipamorelin could reduce the time to recovery of gastrointestinal (GI) function in patients who had undergone partial small and/or large bowel resection [1]. The study was designed to evaluate safety and efficacy in this surgical population. The rationale stems from the compound's ghrelin-mimetic activity, as ghrelin is known to influence GI motility. The trial record does not report outcome data, only the stated expectation that Ipamorelin would shorten recovery time [1].

Ipamorelin and post-operative ileus management

A separate clinical trial examined the safety and efficacy of Ipamorelin in the management of post-operative ileus [2]. Post-operative ileus is a temporary impairment of bowel motility following surgery, and the study aimed to determine whether the compound could resolve this condition. As with the bowel resection trial, the record describes the purpose but does not provide results [2]. Both trials represent human clinical research, though no efficacy conclusions can be drawn from the registry entries alone.

Ipamorelin and the GH-IGF-1 axis in performance-enhancing peptide research

A review of performance-enhancing peptides noted that Ipamorelin is among the growth hormone secretagogues (GHS) commonly encountered in clinical practice and online self-administration protocols [3]. The review classifies Ipamorelin alongside GHRP-2, GHRP-6, and hexarelin as agents intended to modulate the GH-IGF-1 axis [3]. This work is a narrative overview and does not present primary experimental data on Ipamorelin itself; it situates the compound within a broader category of unregulated peptides marketed as research compounds [3].

Ipamorelin and cisplatin-induced weight loss in ferrets

An animal study investigated whether ghrelin mimetics, including Ipamorelin, could alleviate weight loss and inhibition of feeding during acute and delayed phases of cisplatin-induced emesis in ferrets [9]. The study also examined the potential of anamorelin, a related compound, to inhibit electrical field stimulation-induced contractions of isolated tissue [9]. This research is animal-only and does not establish effects in humans. The findings are specific to the ferret model and the cisplatin challenge paradigm [9].

Ipamorelin and the hypothalamic-pituitary-testicular axis in cichlid fish

A study in the cichlid fish Oreochromis mossambicus examined the influence of Ipamorelin acetate on the reproductive axis [10]. The objective was to assess the impact of this ghrelin agonist on the hypothalamic-pituitary-testicular axis in this species [10]. This is a non-mammalian model, and the results are not directly translatable to humans. The work contributes to understanding ghrelin signalling in fish, but it does not provide evidence for human applications [10].

Ipamorelin and purity variability in gray market research peptides

An evaluation of research-grade peptides marketed directly to consumers assessed purity, measured abundance, and endotoxin burden using a large independent testing dataset [4]. The study compared these products to compounded and FDA-approved alternatives [4]. While the dataset included various peptides, the findings highlight that gray market preparations can exhibit extensive variability in purity and measured abundance [4]. This is relevant to any laboratory considering the use of such materials, as the actual content may differ from the label. The study did not focus on Ipamorelin specifically, but the general concern applies to the category [4].

Ipamorelin and peptide therapeutics in aging research

A narrative review of therapeutic peptides in gerontology discussed mechanisms and applications for healthy aging, including peptides that target hallmarks such as hormonal decline and tissue repair impairment [5]. Ipamorelin is not named in the abstract, but the review covers the broader class of growth hormone secretagogues and their potential roles [5]. This is a review article and does not present new experimental data on Ipamorelin. It provides context for why peptides like Ipamorelin are studied in aging-related research [5].

Ipamorelin and musculoskeletal injury or athletic performance

Two preprints on peptide therapies for musculoskeletal injuries and athletic performance describe the pharmacological mechanisms, safety profiles, and regulatory status of approved and unapproved peptides marketed directly to patients [6][7]. These reviews include AOD-9604 and other compounds, and they discuss the parallel gray market of unapproved peptides [6][7]. Ipamorelin is part of the broader category of unapproved peptides used in sports medicine, though the abstracts do not provide specific findings on Ipamorelin. The reviews emphasise that clinical adoption has outpaced high-quality evidence for many such compounds [6][7].

Ipamorelin and peptide supplements in sports medicine

A review of peptide supplements and their therapeutic applications in sports medicine noted the rapid growth of the market driven by marketing claims of enhanced performance and accelerated recovery [11]. These peptides are often perceived as low risk despite the absence of efficacy and safety data [11]. Ipamorelin falls within this category of peptides that are popular but lack robust clinical evidence. The review is reference-only and does not provide primary data on Ipamorelin [11].

Ipamorelin and injectable peptides in sports medicine

A structured narrative review of injectable peptides in sports medicine summarised contemporary human and translational evidence from January 2020 onward [12]. It addressed musculoskeletal recovery, tissue repair, and performance enhancement, noting that clinical adoption has outpaced high-quality evidence and regulatory consensus [12]. Ipamorelin is among the injectable peptides discussed in this context, but the abstract does not detail specific findings for the compound. The review is reference-only and highlights the need for more rigorous research [12].

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.